DISC MEDICINE INC.

NASDAQ: IRON (Disc Medicine, Inc.)

Last update: 5 days ago, 2:48AM

84.64

3.38 (4.16%)

Previous Close 81.26
Volume 1,925,406
Price / Book 5.19
52 Weeks Range
40.00 (-52%) — 99.50 (17%)
Diluted EPS (TTM) -3.89
Total Debt/Equity (MRQ) 4.64%
Current Ratio (MRQ) 37.65
Operating Cash Flow (TTM) -101.70 M
Levered Free Cash Flow (TTM) -66.74 M
Return on Assets (TTM) -16.25%
Return on Equity (TTM) -23.33%

AIStockmoo Score

0.2
Value 38% 0.0
From our AI Insight report's view of expected return against risk. info NA
Relative Valuation info NA
Implied Growth info NA
Valuation History info NA
Low debt. Weak profitability. Ample short-term liquidity. Negative cash flow. info
Return on Capital info NA
Timing 38% 0.6
From our AI technical analysis of the chart. info NA
Downtrend over the past year. Trading near its 52-week high. info
Candle Patterns info NA
Trend for Your Holding Period info NA
Sentiment 25% 0.0
No recent price targets, so based on how targets have been revised. info
News Mood info NA
Smart Money NA
Insider Activity info NA
Institutional Flow info NA
Short Interest info NA
Market and sector conditions are poor.
Market environment cautious. info
Sector lagging the market.
Only one pillar has a clear reading, so the score is unchanged.
Not in score
Price is high against its 52-week average. Down over 5 years. info
Trend up on all three terms. Short-term momentum rising. info
Price is near resistance. Levels trending down. info
Final Score 0.20

Market Trend

Short Term Medium Term
Industry Biotechnology (US) Mixed Bullish
Biotechnology (Global) Mixed Bullish
Stock Disc Medicine, Inc. Mixed Bullish

Similar Stocks

Stock Market Cap DY P/E (TTM) P/B
IRON - - - 5.19
OPT 583 M - - 4.31
OCUP 51 M - - 0.870
CTMX - - - 1.55
ZYME - - - 7.29
PBYI - - - 2.73

Select this tab to load the latest available analysis.

Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs), including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.

Sector Healthcare
Industry Biotechnology
Investment Style Small Core
% Held by Insiders 10.65%
% Held by Institutions 99.13%

No data within this time range.

No data within this time range.

Recent Signals candle patterns and EMA crosses

▲ Bullish EMA cross 9 sessions ago · 28 Oct
Medium term · EMA 20/50
The 20-day EMA crossed above the 50-day: the medium-term trend turned up.
▲ Golden cross 9 sessions ago · 28 Oct
Long term · EMA 50/200
The 50-day EMA crossed above the 200-day, a widely watched sign that the long-term trend has turned up.

AI Technical Analysis

Portfolio

AI Template

Your price alert

Risk Profile

| | | | |
Conservative
Moderate Conservative
Moderate
Moderate Aggressive
Aggressive
Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)

Disclaimer: The above is for illustrative purposes only and is NOT investment advice. Seek advice from a qualified financial professional.

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

52W Range
 
52WL
 
52WH
SL
EP
TP1
TP2

All alert prices are within 52 weeks price range

Realized Profit -
Unrealized Profit -
Dividend Received 2026 -
Total Profit -
Avg. Return -
Quantity (Buy) -
Avg. Price (Buy) -
Quantity (Sold) -
Avg. Price (Sold) -
No stocks matching your criteria